Skip to main content
Premium Trial:

Request an Annual Quote

Zerhouni Leaves NIH; Koepfgen Resigns from Thermo Fisher Board, Novotny Joins Protein Discovery's SAB, Asbury to Direct Marketing at Protea

NEW YORK (GenomeWeb News) - National Institutes of Health Director Elias Zerhounisaid this week that he will resign from his position at the end of October "to pursue writing projects and explore other professional opportunities."

Zerhouni said that his departure is timed to synchronize with the end of the current White House administration and that he does not consider the move to be a resignation.

Raynard Kington, deputy director of NIH, is expected to serve as acting director until a new White House names his successor.

 

 
Bruce Koepfgen has resigned from the board of Thermo Fisher Scientific effective Sept. 30, the company said in a document filed with the US Securities and Exchange Commission last week.
 
Koepfgen was a member of the board of Fisher Scientific International when it merged with Thermo Electron in 2006, and was elected to the board of Thermo Fisher in 2006. Koepfgen is a member of the audit committee of the board.
 

 
Milos Novotny has been appointed to Protein Discovery’s scientific advisory board. Novotny is a professor at the department of chemistry at Indiana University, where he also is Lilly Chemistry Alumni Chair and an adjunct professor of medicine. He is director of the National Center for Glycomics and Glycoproteomics and of the Institute for Pheromone Research. The company expects to lean on Novotny’s knowledge of electrophoretic and chromatographic separations for its sample preparation and mass spectrometry endeavors.
 

 
 
Protea Biosciences has named Reid Asbury to be director of marketing, the company said this week. Asbury was a manager of protein and genomic sciences at GE Healthcare between 2000 and 2008.
 

 
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.